* pregnant or nursing female. * patients with history of allergy, hypersensitivity, or any serious reaction to study medication * patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. * patient previously enrolled into this study. * patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or hiv. * patients with a life expectancy judged to be less than five days * alt/ast \> 5 times the upper limit of normal * stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr \< 30) * patients not likely to complete the trial as per judgment of the investigator.

* pregnant or nursing female. * patients with history of allergy, hypersensitivity, or any serious reaction to study medication * patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. * patient previously enrolled into this study. * patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or hiv. * patients with a life expectancy judged to be less than five days * alt/ast \> 5 times the upper limit of normal * stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr \< 30) * patients not likely to complete the trial as per judgment of the investigator.

- pregnant or nursing female. - patients with history of allergy, hypersensitivity, or any serious reaction to study medication - patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. - patient previously enrolled into this study. - patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or hiv. - patients with a life expectancy judged to be less than five days - alt/ast > 5 times the upper limit of normal - stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30) - patients not likely to complete the trial as per judgment of the investigator.

- pregnant or nursing female. - patients with history of allergy, hypersensitivity, or any serious reaction to study medication - patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. - patient previously enrolled into this study. - patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or hiv. - patients with a life expectancy judged to be less than five days - alt/ast > 5 times the upper limit of normal - stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr < 30) - patients not likely to complete the trial as per judgment of the investigator.